PCH
STOK icon

Polar Capital Holdings’s Stoke Therapeutics STOK Stock Holding History

Polar Capital Holdings’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36.9M Sell
1,132,511
-136,620
-11% -$4.48M 0.13% 121
2025
Q4 		$40.3M Sell
1,269,131
-54,339
-4% -$1.63M 0.16% 112
2025
Q3 		$31.1M Buy
1,323,470
+439,824
+50% +$7.54M 0.15% 114
2025
Q2 		$10M Buy
+883,646
New +$8.39M 0.05% 192

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Polar Capital Holdings's STOK Position: Q1 2026 in Review

Polar Capital Holdings reduced its Stoke Therapeutics (STOK) stake by 11% in Q1 2026, selling an estimated $4.48M and leaving 1,132,511 shares worth $36.9M. The position accounts for 0.13% of the portfolio, ranked #121.

Polar Capital Holdings first reported a position in STOK in Q2 2025 and has held it in 4 quarters since. The position peaked at $40.3M in Q4 2025. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • Polar Capital Holdings held 1,132,511 shares of Stoke Therapeutics worth $36.9M as of Q1 2026.
  • Polar Capital Holdings sold 136,620 Stoke Therapeutics shares in Q1 2026, an estimated $4.48M.
  • Stoke Therapeutics made up 0.13% of Polar Capital Holdings's portfolio in Q1 2026, its #121 holding.
  • Polar Capital Holdings first reported a position in Stoke Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Polar Capital Holdings's Stoke Therapeutics position peaked at $40.3M in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Polar Capital Holdings's 13F filing for Q1 2026, filed 15 May 2026.